Locations

Biography

Dr. Amin's clinical interests include studying the effects of jaundice, nutrition, and environmental toxins on developing nervous system in neonates. His future interests include long-term neurodevelopmental outcomes, such as language, autism, ADHD, central auditory processing disorders, etc. of premature and late preterm neonates.

Research

Dr. Amin's research interests include the effects of jaundice, nutritional, and environmental toxins on the developing nervous system in neonates using auditory brainstem responses. He is specifically interested in identifying bilirubin biochemical markers associated with bilirubin-induced neurotoxicity. He is evaluating jaundice associated dental developmental outcomes in premature and term infants as part of NIH-funded project. He is also evaluating jaundice associated transient and/or permanent auditory toxicity in premature and term neonates as part of NIH-funded international projects. In addition to assessing early neurodevelopmental outcomes, he is actively investigating visual evoked potentials, language disorders, autism, ADHD, executive function, cognition, central auditory processing disorders, and other developmental outcomes of premature and term neonates. Dr. Amin is also investigating the beneficial antioxidant effect of jaundice on neonatal morbidities. Dr. Amin is interested in genetic polymorphism and ethnic differences in bilirubin production and susceptibility to bilirubin-induced neurotoxicity. He explored a new technique using fluorescent spectrophotometry to measure free bilirubin levels, a more specific marker of bilirubin-induced neurotoxicity. He studies the effect of lead, gadolinium, and other environmental metals and toxins on neonatal outcomes and developing nervous system; effect of nutrition specifically iron and Vitamin D deficiency on neonatal outcomes; effect of inflammation and hormonal deficiency on neonatal outcomes and brain development. In addition, he is the PI of four randomized trials (RCT): Double blind RCT of lipid administration, Double blind RCT of iron supplementation, Double blind RCT of chest shielding, and an interventional trial of ceftriaxone. He is the co-investigator for the NIH funded ECHO project. His work is supported by NICHD, CTSI, and NIDCR.